Birth control pills associated with breast cancer risk in BRCA1 mutation carriers

December 03, 2002

Women who carry mutations in the BRCA1 breast cancer susceptibility gene and have a history of oral contraceptive use may have an increased risk of early-onset breast cancer, according to a large-scale study in the December 4 issue of the Journal of the National Cancer Institute.

Women with BRCA1 and BRCA2 mutations have a 50% to 80% lifetime risk of developing breast cancer. This risk may be modified by factors that influence the level of hormones produced by the body. Whether this risk is modified by exogenous hormones, such as oral contraceptives or hormone replacement therapy, is unknown. Long-term oral contraceptive use has been associated with a modest increase in the risk of breast cancer in the general population and a decrease in the risk of ovarian cancer.

To examine whether the use of oral contraceptives is associated with the risk of hereditary breast cancer, Steven A. Narod, M.D., of the Sunnybrook and Women's College Health Sciences Centre and the University of Toronto, and his colleagues looked at history of oral contraceptive use among 1,311 women with BRCA1 or BRCA2 mutations who had breast cancer and 1,311 mutation carriers without breast cancer. The women were recruited from 52 centers in 11 countries.

Among women with BRCA1 mutations, those who used oral contraceptives for 5 or more years had a 33% increase in the risk of breast cancer, compared with women who had never used oral contraceptives. The risk was also elevated in women who used contraceptives before age 30, women who were diagnosed with breast cancer before age 40, and women who first used oral contraceptives before 1975. In contrast, Narod and his colleagues did not find any increase in breast cancer risk in BRCA2 mutation carriers, but they say that more studies should be done to confirm these findings.

The authors say that for women carrying a BRCA1 mutation, age should be an important consideration when prescribing an oral contraceptive. The new findings suggest that "oral contraceptive use after age 30 is not likely to increase the risk of breast cancer among BRCA1 mutation carriers and can be used safely to reduce the risk of ovarian cancer," they conclude.
-end-
Contact: Janet Wong, University of Toronto, (416) 978-5949; fax: 416-978-7430, jf.wong@utoronto.ca

Narod S, Dubé M, Klijn J, Lubinski J, Lynch H, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.